サウジアラビア、トルコ、エジプトの体外診断(IVD)品質管理市場
Market Size in USD Billion
CAGR : %
予測期間 |
2023 –2030 |
市場規模(基準年) |
USD 867.09 Thousand |
Market Size (Forecast Year) |
USD 1,260.66 Thousand |
CAGR |
|
主要市場プレーヤー |
>サウジアラビア、トルコ、エジプトの体外診断 (IVD) 品質管理市場、製品およびサービス別 (品質管理製品および品質管理サービス)、アプリケーション別 (臨床化学、免疫化学、血液学、分子診断、凝固/止血、微生物学、その他)、セクター別 (臨床および非臨床)、エンドユーザー別 (臨床検査室、学術研究機関、血液銀行、バイオテクノロジー産業、製薬産業、その他) - 2030 年までの業界動向および予測。
サウジアラビア、トルコ、エジプトの体外診断(IVD)品質管理市場の分析と規模
サウジアラビア、トルコ、エジプト全土で慢性疾患の罹患率が上昇していることから、市場の需要が高まっています。より良い医療サービスを求める医療費の増加も、市場の成長に寄与しています。主要な市場プレーヤーは、この重要な時期にさまざまな製品の発売と承認に注力しています。さらに、品質管理サービスの向上の増加も、IVD 品質管理市場の需要増加に寄与しています。
サウジアラビア、トルコ、エジプトの体外診断(IVD)品質管理市場は、2023年から2030年の予測期間に市場が成長すると予想されています。データブリッジマーケットリサーチは、市場は2023年から2030年の予測期間に4.8%のCAGRで成長し、2022年の867.09千米ドルから2030年には1,260.66千米ドルに達すると分析しています。
レポートメトリック |
詳細 |
予測期間 |
2023年から2030年 |
基準年 |
2022 |
歴史的な年 |
2021 (2015~2020年にカスタマイズ可能) |
定量単位 |
収益(千米ドル) |
対象セグメント |
製品およびサービス(品質管理製品および品質管理サービス)、用途(臨床化学、免疫化学、血液学、分子診断、凝固/止血、微生物学、その他)、セクター(臨床および非臨床)、エンドユーザー(臨床検査室、学術研究機関、血液銀行、バイオテクノロジー産業、製薬産業、その他) |
対象国 |
サウジアラビア、トルコ、エジプト |
対象となる市場プレーヤー |
この市場で取引している主要企業としては、Bio-Rad Laboratories, Inc、Siemens Healthcare Private Limited、Sysmex Europe SE、Randox Laboratories Ltd.、Sera Care、Thermo Fisher Scientific Inc.、Beckman Coulter, Inc.、Technopath Clinical Diagnostics、DiaSorin SpA、Agappe Diagnostics Ltd、Spectrum Diagnosticsなどがあります。 |
市場の定義
体外診断用製品とは、病気やその続発症を治療、緩和、治療、予防するために、健康状態の判定を含む病気やその他の症状の診断に使用することを目的とした試薬、器具、システムです。このような製品は、人体から採取した検体の収集、準備、検査に使用することを目的としています。
IVD quality controls are samples/materials used to validate the reliability of the IVD testing system to ensure the accuracy of test results and evaluate the impact of factors such as environmental conditions and operator’s performance on test results. Moreover, they can also be used to monitor a patient’s health, cure diseases, and also enable medical professionals to identify the most effective treatment procedure or therapy for the patient.
In Vitro Diagnostics (IVD) Quality Control Market Dynamics
This section deals with understanding the market drivers, opportunities, restraints and challenges. All of this is discussed in detail as below:
Drivers
- Rising Prevalence of Chronic Diseases Across Saudi Arabia, Turkey, and Egypt
Chronic diseases and conditions are on the rise globally. An aging population and a sedentary lifestyle are contributing to a steady increase in long-term health problems. An increasing prevalence of chronic and infectious diseases has led to the launch of rapid diagnostic and testing tools by leading market players. Besides, the rising adoption of self-test and point-of-care devices is further accelerating the growth of in-vitro diagnostics devices across the globe
Thus, the increasing number of chronic disease are expected to accelerate the growth of the IVD quality control market significantly in the nearby future.
- Rising Adoption of Quality Control Solutions in Laboratories and Hospitals
Laboratory testing of patient samples can be a complex procedure, depending on clinical analysis, microbiological study, or blood banking testing among other facets of the clinical laboratory. Quality control (QC) is one of the most important impacts on laboratory testing-it ensures both the precision and accuracy of patient sample results. The integrity of quality control samples is important to both management of overall quality as well as to meeting requirements of proficiency testing.
Thus, the rising adoption of quality control solutions in laboratories and hospitals is expected to drive the market growth.
Opportunities
-
Rise in Strategic Acquisition and Partnership among Organizations
Recently, different organizations are stepping forward for partnership and collaboration to develop IVDs that are essential for detecting diseases. Not only can this, with the help of partnerships and agreements, both the companies develop a new suite of technologies and platforms that will help to detect diseases.
With the help of a long-term agreement, both companies can provide dimensional pricing IVDs in response to consumer demand in the market. Such partnership and mutual agreement not only benefit both the companies but are also creating a lot of opportunities for the market to grow.
-
Rising Research and Development Activities
Across the globe, the spending on research and development activities is escalating owing to public health expenditure with economic performance. Whereas, the healthcare industry ranks second among all industries when it comes to the amount it spends on research and development. Rising healthcare expenditure has further resulted in better provision of research and development opportunities. Consequently, it has enhanced the demand for IVD regulatory affairs outsourcing services across the region.
Restraints/Challenges
- High Cost Related to Quality Control and Maintenance of IVD
In vitro diagnostics (IVD) are tests done on samples such as blood or tissue that have been taken from the human body. In vitro diagnostics can detect diseases or other conditions, and can be used to monitor a person's overall health to help cure, treat, or prevent diseases.
IVD of analytes originating from body specimens, including blood and tissue biopsies, is used alone or in combination with clinical investigations and is perceived as an important tool for high-quality medical outcomes, hence maintaining of IVD and quality control of IVD devices costs high for carrying out accurate tests.
Hence, the rising cost of the maintenance of IVD has become a deciding factor for the companies in the servicing process, which is further restraining the growth of the market to an extent.
- Stringent Regulations Regarding IVD in Saudi Arabia, Turkey, and Egypt
The use of IVDs across the globe is rapidly increasing, with the growth of the aged population and several chronic diseases which are preventable by early diagnosis and timely treatments. At the same time, the players of the IVD devices in the market have to follow certain regulations to get approval from the upper authorities for the launching of the product in a region. These stringent guidelines need to be followed, and this is one of the most difficult tasks among all the steps. The pre-market approval of various medical devices varies from one country to another.
Therefore, the stringent rules & regulations for product approval act as restraints for the growth of the market.
Recent Development
- In February 2023, Siemens Healthineers, a leading medical technology company, and Unilabs, a leading diagnostic services provider, announced a multi-year agreement valued at over €200 thousand. Unilabs has invested in Siemens Healthineers top-notch technology and will acquire more than 400 laboratory analyzers to further improve its laboratory infrastructure to offer an unparalleled service to its customers. This partnership has helped for latest diagnostic testing infrastructure to improve patients’ care.
- In July 2021, Thermo Fisher Scientific, the world leader in serving science, announced a collaboration with Ortho Clinical Diagnostics to promote and distribute Thermo Scientific MAS Quality Controls and LabLink xL Quality Assurance Software for use with Ortho Clinical Diagnostics VITROS analyzers. This has helped the company to increase their global presence in the market.
Saudi Arabia, Turkey, and Egypt in Vitro Diagnostics (IVD) Quality Control Market Scope
Saudi Arabia, Turkey, and Egypt in vitro diagnostics (IVD) quality control market is segmented into four notable segments such as product and services, application, type, sector and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.
Product and Services
- Quality Control Products
- Quality Control Services
On the basis of products and services, the Saudi Arabia, Turkey, and Egypt In vitro diagnostics (IVD) quality control market is segmented into quality control products and quality control services.
Applications
- Clinical Chemistry
- Immunochemistry
- Hematology
- Molecular Diagnostics
- Coagulation/Hemostasis
- Microbiology
- Others
Based on applications, the Saudi Arabia, Turkey, and Egypt In vitro diagnostics (IVD) quality control market is segmented into clinical chemistry, immunochemistry, hematology, molecular diagnostics, coagulation/hemostasis, microbiology, and others.
Sector
- Clinical
- Non-Clinical
Based on sector, the Saudi Arabia, Turkey, and Egypt In vitro diagnostics (IVD) quality control market is segmented into clinical and non-clinical.
End User
- Clinical Laboratories
- Academic And Research Institutes
- Blood Banks
- Biotechnology Industry
- Pharmaceutical Industry
- Others
Based on end users, the Saudi Arabia, Turkey, and Egypt In vitro diagnostics (IVD) quality control market is segmented into clinical laboratories, academic and research institutes, blood banks, biotechnology industry, pharmaceutical industry, and others.
Competitive Landscape and In Vitro Diagnostics (IVD) Quality Control Market Share Analysis
The in vitro diagnostics (IVD) quality control market competitive landscape provides details by the competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus on the ataxia market.
体外診断 (IVD) 品質管理市場で活動している主要企業には、Bio-Rad Laboratories, Inc、Siemens Healthcare Private Limited、Sysmex Europe SE、Randox Laboratories Ltd.、Sera Care、Thermo Fisher Scientific Inc.、Beckman Coulter, Inc.、Technopath Clinical Diagnostics、DiaSorin SpA、Agappe Diagnostics Ltd、Spectrum Diagnostics などがあります。
SKU-
世界初のマーケットインテリジェンスクラウドに関するレポートにオンラインでアクセスする
- インタラクティブなデータ分析ダッシュボード
- 成長の可能性が高い機会のための企業分析ダッシュボード
- カスタマイズとクエリのためのリサーチアナリストアクセス
- インタラクティブなダッシュボードによる競合分析
- 最新ニュース、更新情報、トレンド分析
- 包括的な競合追跡のためのベンチマーク分析のパワーを活用
目次
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF SAUDI ARABIA, TURKEY, AND EGYPT IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 SAUDI ARABIA PRODUCTS AND SERVICES, LIFELINE CURVE
2.8 EGYPT PRODUCTS AND SERVICES, LIFELINE CURVE
2.9 TURKEY PRODUCTS AND SERVICES, LIFELINE CURVE
2.1 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.11 DBMR MARKET POSITION GRID
2.12 MARKET TESTING TYPE COVERAGE GRID
2.13 VENDOR SHARE ANALYSIS
2.14 SECONDARY SOURCES
2.15 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL'S MODEL
4.2 PORTER'S 5 FORCES
4.3 INDUSTRY INSIGHTS
5 REGULATORY GUIDELINES FOR IN VITRO DIAGNOSTICS QUALITY CONTROL
5.1 REGULATIONS IN SAUDI ARABIA
5.2 REGULATIONS IN TURKEY
5.3 REGULATIONS IN EGYPT
5.3.1 MEDICAL DEVICE REGISTRATION IN EGYPT, THE PROCESS IN BRIEF:
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 RISING PREVALENCE OF CHRONIC DISEASES ACROSS SAUDI ARABIA, TURKEY, AND EGYPT
6.1.2 RISING ADOPTION OF QUALITY CONTROL SOLUTIONS IN LABORATORIES AND HOSPITALS
6.1.3 ADVANCEMENTS IN TECHNOLOGY LEADING TO THE DEVELOPMENT OF NEW AND ADVANCED DIAGNOSTIC PRODUCTS
6.1.4 RISING USE OF QUALITY CONTROL IN MOLECULAR DIAGNOSTICS
6.2 RESTRAINTS
6.2.1 HIGH COST RELATED TO QUALITY CONTROL AND MAINTENANCE OF IVD
6.2.2 STRINGENT REGULATIONS REGARDING IVD IN SAUDI ARABIA, TURKEY, AND EGYPT
6.3 OPPORTUNITIES
6.3.1 RISE IN STRATEGIC ACQUISITION AND PARTNERSHIP AMONG ORGANIZATIONS
6.3.2 RISING RESEARCH AND DEVELOPMENT ACTIVITIES
6.4 CHALLENGES
6.4.1 LACK OF INFRASTRUCTURE IN HEALTHCARE SERVICE
6.4.2 SHORTAGE OF SKILLED PERSONNEL FOR HANDLING QUALITY CONTROL OF IN VITRO DIAGNOSTIC DEVICES.
7 SAUDI ARABIA, TURKEY, AND EGYPT IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET, BY PRODUCT AND SERVICES
7.1 OVERVIEW
7.2 QUALITY CONTROL PRODUCTS
7.2.1 SERUM/PLASMA-BASED CONTROL
7.2.2 WHOLE BLOOD-BASED CONTROLS
7.2.3 URINE-BASED CONTROLS
7.2.4 OTHER CONTROLS
7.2.5 INTERNAL QUALITY CONTROL
7.2.6 EXTERNAL QUALITY CONTROL
7.3 QUALITY CONTROL SERVICES
8 SAUDI ARABIA, TURKEY, AND EGYPT IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET, BY APPLICATION
8.1 OVERVIEW
8.2 CLINICAL CHEMISTRY
8.3 IMMUNOCHEMISTRY
8.4 HEMATOLOGY
8.5 MOLECULAR DIAGNOSTICS
8.5.1 QUALITY CONTROL PRODUCTS
8.5.1.1 INTERNAL QUALITY CONTROL
8.5.1.2 EXTERNAL QUALITY CONTROL
8.5.2 QUALITY CONTROL SERVICES
8.6 COAGULATION/HEMOSTASIS
8.7 MICROBIOLOGY
8.8 OTHERS
9 SAUDI ARABIA, TURKEY, AND EGYPT IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET, BY SECTOR
9.1 OVERVIEW
9.2 CLINICAL
9.3 NON-CLINICAL
10 SAUDI ARABIA, TURKEY, AND EGYPT IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET, BY END USER
10.1 OVERVIEW
10.2 CLINICAL LABORATORIES
10.3 ACADEMIC AND RESEARCH INSTITUTES
10.4 PHARMACEUTICAL INDUSTRY
10.5 BIOTECHNOLOGY INDUSTRY
10.6 BLOOD BANKS
10.7 OTHERS
11 SAUDI ARABIA, TURKEY, AND EGYPT IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET, COMPANY LANDSCAPE
11.1 COMPANY SHARE ANALYSIS: SAUDI ARABIA
11.2 COMPANY SHARE ANALYSIS: EGYPT
11.3 COMPANY SHARE ANALYSIS: TURKEY
12 SWOT ANALYSIS
13 TURKEY IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET, COMPANY PROFILES
13.1 THERMO FISHER SCIENTIFIC INC.
13.1.1 COMPANY SNAPSHOT
13.1.2 REVENUE ANALYSIS
13.1.3 PRODUCT PORTFOLIO
13.1.4 RECENT DEVELOPMENTS
13.2 SIEMENS HEALTHCARE GMBH
13.2.1 COMPANY SNAPSHOT
13.2.2 REVENUE ANALYSIS
13.2.3 PRODUCT PORTFOLIO
13.2.4 RECENT DEVELOPMENT
13.3 BIO-RAD LABORATORIES, INC.
13.3.1 COMPANY SNAPSHOT
13.3.2 REVENUE ANALYSIS
13.3.3 PRODUCT PORTFOLIO
13.3.4 RECENT DEVELOPMENT
13.4 BECKMAN COULTER, INC.
13.4.1 COMPANY SNAPSHOT
13.4.2 PRODUCT PORTFOLIO
13.4.3 RECENT DEVELOPMENT
13.5 SYSMEX CORPORATION
13.5.1 COMPANY SNAPSHOT
13.5.2 REVENUE ANALYSIS
13.5.3 PRODUCT PORTFOLIO
13.5.4 RECENT DEVELOPMENT
13.6 AGAPPE DIAGNOSTICS LTD
13.6.1 COMPANY SNAPSHOT
13.6.2 PRODUCT PORTFOLIO
13.6.3 RECENT DEVELOPMENT
13.7 DIASORIN MOLECULAR LLC.
13.7.1 COMPANY SNAPSHOT
13.7.2 PRODUCT PORTFOLIO
13.7.3 RECENT DEVELOPMENT
13.8 RANDOX LABORATORIES LTD.
13.8.1 COMPANY SNAPSHOT
13.8.2 PRODUCT PORTFOLIO
13.8.3 RECENT DEVELOPMENT
13.9 SERA CARE
13.9.1 COMPANY SNAPSHOT
13.9.2 PRODUCT PORTFOLIO
13.9.3 RECENT DEVELOPMENT
13.1 SPECTRUM DIAGNOSTICS
13.10.1 COMPANY SNAPSHOT
13.10.2 PRODUCT PORTFOLIO
13.10.3 RECENT DEVELOPMENT
13.11 TECHNOPATH CLINICAL DIAGNOSTICS
13.11.1 COMPANY SNAPSHOT
13.11.2 PRODUCT PORTFOLIO
13.11.3 RECENT DEVELOPMENT
14 QUESTIONNAIRE
15 RELATED REPORTS
図表一覧
FIGURE 1 SAUDI ARABIA, TURKEY, AND EGYPT IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET: SEGMENTATION
FIGURE 2 SAUDI ARABIA, TURKEY, AND EGYPT IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET: DATA TRIANGULATION
FIGURE 3 SAUDI ARABIA, TURKEY, AND EGYPT IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET: DROC ANALYSIS
FIGURE 4 SAUDI ARABIA IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET: COUNTRY MARKET ANALYSIS
FIGURE 5 EGYPT IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET: COUNTRY MARKET ANALYSIS
FIGURE 6 TURKEYS IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET: COUNTRY MARKET ANALYSIS
FIGURE 7 SAUDI ARABIA, TURKEY, AND EGYPT IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 8 SAUDI ARABIA, TURKEY, AND EGYPT IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 9 SAUDI ARABIA, TURKEY, AND EGYPT IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET: DBMR MARKET POSITION GRID
FIGURE 10 SAUDI ARABIA, TURKEY, AND EGYPT IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET: MARKET TESTING TYPE COVERAGE GRID
FIGURE 11 SAUDI ARABIA, TURKEY, AND EGYPT IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET: VENDOR SHARE ANALYSIS
FIGURE 12 SAUDI ARABIA, TURKEY, AND EGYPT IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET: SEGMENTATION
FIGURE 13 RISING PREVALENCE OF CHRONIC DISEASES ACROSS SAUDI ARABIA IS EXPECTED TO DRIVE THE SAUDI ARABIA IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET IN THE FORECAST PERIOD
FIGURE 14 RISING ADOPTION OF QUALITY CONTROL SOLUTIONS IN LABORATORIES AND HOSPITALS IS EXPECTED TO DRIVE THE TURKEY IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET IN THE FORECAST PERIOD IN THE FORECAST PERIOD
FIGURE 15 ADVANCEMENTS IN TECHNOLOGY LEADING TO THE DEVELOPMENT OF NEW AND ADVANCED DIAGNOSTIC PRODUCTS ARE EXPECTED TO DRIVE THE EGYPT IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET IN THE FORECAST PERIOD IN THE FORECAST PERIOD
FIGURE 16 THE PRODUCT AND SERVICES TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE SAUDI ARABIA IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET IN 2023 & 2030
FIGURE 17 THE PRODUCT AND SERVICES TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE TURKEY IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET IN 2023 & 2030
FIGURE 18 THE PRODUCT AND SERVICES TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EGYPT IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET IN 2023 & 2030
FIGURE 19 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF SAUDI ARABIA, TURKEY, AND EGYPT IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET
FIGURE 20 SAUDI ARABIA, IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET, BY PRODUCTS AND SERVICES, 2022
FIGURE 21 TURKEY, IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET, BY PRODUCTS AND SERVICES, 2022
FIGURE 22 EGYPT, IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET, BY PRODUCTS AND SERVICES, 2022
FIGURE 23 SAUDI ARABIA IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET, BY PRODUCTS AND SERVICES, 2023-2030 (USD THOUSAND)
FIGURE 24 TURKEY IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET, BY PRODUCTS AND SERVICES, 2023-2030 (USD THOUSAND)
FIGURE 25 EGYPT IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET, BY PRODUCTS AND SERVICES, 2023-2030 (USD THOUSAND)
FIGURE 26 SAUDI ARABIA IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET, BY PRODUCTS AND SERVICES, CAGR (2023-2030)
FIGURE 27 TURKEY IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET, BY PRODUCTS AND SERVICES, CAGR (2023-2030)
FIGURE 28 EGYPT IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET, BY PRODUCTS AND SERVICES, CAGR (2023-2030)
FIGURE 29 SAUDI ARABIA, TURKEY AND EGYPT IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET, BY PRODUCTS AND SERVICES, LIFELINE CURVE
FIGURE 30 TURKEY IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET, BY PRODUCTS AND SERVICES, LIFELINE CURVE
FIGURE 31 EGYPT IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET, BY PRODUCTS AND SERVICES, LIFELINE CURVE
FIGURE 32 SAUDI ARABIA IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET, BY APPLICATION, 2022
FIGURE 33 TURKEY IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET, BY APPLICATION, 2022
FIGURE 34 EGYPT IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET, BY APPLICATION, 2022
FIGURE 35 SAUDI ARABIA IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET, BY APPLICATION, 2023-2030 (USD THOUSAND)
FIGURE 36 TURKEY IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET, BY APPLICATION, 2023-2030 (USD THOUSAND)
FIGURE 37 EGYPT IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET, BY APPLICATION, 2023-2030 (USD THOUSAND)
FIGURE 38 SAUDI ARABIA, IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET, BY APPLICATION, CAGR (2023-2030)
FIGURE 39 TURKEY, IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET, BY APPLICATION, CAGR (2023-2030)
FIGURE 40 EGYPT, IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET, BY APPLICATION, CAGR (2023-2030)
FIGURE 41 SAUDI ARABIA, IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET, BY APPLICATION, LIFELINE CURVE
FIGURE 42 TURKEY, IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET, BY APPLICATION, LIFELINE CURVE
FIGURE 43 EGYPT, IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET, BY APPLICATION, LIFELINE CURVE
FIGURE 44 SAUDI ARABIA, IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET, BY SECTOR, 2022
FIGURE 45 TURKEY, IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET, BY SECTOR, 2022
FIGURE 46 EGYPT, IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET, BY SECTOR, 2022
FIGURE 47 SAUDI ARABIA, IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET, BY SECTOR, 2023-2030 (USD THOUSAND)
FIGURE 48 TURKEY, IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET, BY SECTOR, 2023-2030 (USD THOUSAND)
FIGURE 49 EGYPT, IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET, BY SECTOR, 2023-2030 (USD THOUSAND)
FIGURE 50 SAUDI ARABIA IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET, BY SECTOR, CAGR (2023-2030)
FIGURE 51 TURKEY IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET, BY SECTOR, CAGR (2023-2030)
FIGURE 52 EGYPT IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET, BY SECTOR, CAGR (2023-2030)
FIGURE 53 SAUDI ARABIA, IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET, BY SECTOR, LIFELINE CURVE
FIGURE 54 TURKEY IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET, BY SECTOR, LIFELINE CURVE
FIGURE 55 EGYPT IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET, BY SECTOR, LIFELINE CURVE
FIGURE 56 SAUDI ARABIA, IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET, BY END USER, 2022
FIGURE 57 TURKEY IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET, BY END USER, 2022
FIGURE 58 EGYPT IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET, BY END USER, 2022
FIGURE 59 SAUDI ARABIA, IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET, BY END USER, 2023-2030 (USD THOUSAND)
FIGURE 60 TURKEY, IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET, BY END USER, 2023-2030 (USD THOUSAND)
FIGURE 61 EGYPT, IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET, BY END USER, 2023-2030 (USD THOUSAND)
FIGURE 62 SAUDI ARABIA IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET, BY END USER, CAGR (2023-2030)
FIGURE 63 TURKEY IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET, BY END USER, CAGR (2023-2030)
FIGURE 64 EGYPT IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET, BY END USER, CAGR (2023-2030)
FIGURE 65 SAUDI ARABIA, IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET, BY END USER, LIFELINE CURVE
FIGURE 66 TURKEY, IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET, BY END USER, LIFELINE CURVE
FIGURE 67 EGYPT, IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET, BY END USER, LIFELINE CURVE
FIGURE 68 SAUDI ARABIA IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET: COMPANY SHARE 2022 (%)
FIGURE 69 EGYPT IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET: COMPANY SHARE 2022 (%)
FIGURE 70 TURKEY IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET: COMPANY SHARE 2022 (%)
調査方法
データ収集と基準年分析は、大規模なサンプル サイズのデータ収集モジュールを使用して行われます。この段階では、さまざまなソースと戦略を通じて市場情報または関連データを取得します。過去に取得したすべてのデータを事前に調査および計画することも含まれます。また、さまざまな情報ソース間で見られる情報の不一致の調査も含まれます。市場データは、市場統計モデルと一貫性モデルを使用して分析および推定されます。また、市場シェア分析と主要トレンド分析は、市場レポートの主要な成功要因です。詳細については、アナリストへの電話をリクエストするか、お問い合わせをドロップダウンしてください。
DBMR 調査チームが使用する主要な調査方法は、データ マイニング、データ変数が市場に与える影響の分析、および一次 (業界の専門家) 検証を含むデータ三角測量です。データ モデルには、ベンダー ポジショニング グリッド、市場タイムライン分析、市場概要とガイド、企業ポジショニング グリッド、特許分析、価格分析、企業市場シェア分析、測定基準、グローバルと地域、ベンダー シェア分析が含まれます。調査方法について詳しくは、お問い合わせフォームから当社の業界専門家にご相談ください。
カスタマイズ可能
Data Bridge Market Research は、高度な形成的調査のリーダーです。当社は、既存および新規のお客様に、お客様の目標に合致し、それに適したデータと分析を提供することに誇りを持っています。レポートは、対象ブランドの価格動向分析、追加国の市場理解 (国のリストをお問い合わせください)、臨床試験結果データ、文献レビュー、リファービッシュ市場および製品ベース分析を含めるようにカスタマイズできます。対象競合他社の市場分析は、技術ベースの分析から市場ポートフォリオ戦略まで分析できます。必要な競合他社のデータを、必要な形式とデータ スタイルでいくつでも追加できます。当社のアナリスト チームは、粗い生の Excel ファイル ピボット テーブル (ファクト ブック) でデータを提供したり、レポートで利用可能なデータ セットからプレゼンテーションを作成するお手伝いをしたりすることもできます。